Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

94 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.
Vétizou M, Pitt JM, Daillère R, Lepage P, Waldschmitt N, Flament C, Rusakiewicz S, Routy B, Roberti MP, Duong CP, Poirier-Colame V, Roux A, Becharef S, Formenti S, Golden E, Cording S, Eberl G, Schlitzer A, Ginhoux F, Mani S, Yamazaki T, Jacquelot N, Enot DP, Bérard M, Nigou J, Opolon P, Eggermont A, Woerther PL, Chachaty E, Chaput N, Robert C, Mateus C, Kroemer G, Raoult D, Boneca IG, Carbonnel F, Chamaillard M, Zitvogel L. Vétizou M, et al. Among authors: flament c. Science. 2015 Nov 27;350(6264):1079-84. doi: 10.1126/science.aad1329. Epub 2015 Nov 5. Science. 2015. PMID: 26541610 Free PMC article.
Generation of monocyte-derived dendritic cells from patients with renal cell cancer: modulation of their functional properties after therapy with biological response modifiers (IFN-alpha plus IL-2 and IL-12).
Merad M, Angevin E, Wolfers J, Flament C, Lorenzi I, Triebel F, Escudier B, Zitvogel L. Merad M, et al. Among authors: flament c. J Immunother. 2000 May-Jun;23(3):369-78. doi: 10.1097/00002371-200005000-00010. J Immunother. 2000. PMID: 10838666 Clinical Trial.
Exosomes in cancer immunotherapy: preclinical data.
Andre F, Andersen M, Wolfers J, Lozier A, Raposo G, Serra V, Ruegg C, Flament C, Angevin E, Amigorena S, Zitvogel L. Andre F, et al. Among authors: flament c. Adv Exp Med Biol. 2001;495:349-54. doi: 10.1007/978-1-4615-0685-0_49. Adv Exp Med Biol. 2001. PMID: 11774591 Review. No abstract available.
Tumor-derived exosomes: a new source of tumor rejection antigens.
André F, Schartz NE, Chaput N, Flament C, Raposo G, Amigorena S, Angevin E, Zitvogel L. André F, et al. Among authors: flament c. Vaccine. 2002 Dec 19;20 Suppl 4:A28-31. doi: 10.1016/s0264-410x(02)00384-5. Vaccine. 2002. PMID: 12477425 Review.
[Exosomes and anti-tumour immunotherapy].
Chaput N, Andre F, Schartz NE, Flament C, Angevin E, Escudier B, Zitvogel L. Chaput N, et al. Among authors: flament c. Bull Cancer. 2003 Aug-Sep;90(8-9):695-8. Bull Cancer. 2003. PMID: 14609758 Free article. Clinical Trial. French.
Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells.
André F, Chaput N, Schartz NE, Flament C, Aubert N, Bernard J, Lemonnier F, Raposo G, Escudier B, Hsu DH, Tursz T, Amigorena S, Angevin E, Zitvogel L. André F, et al. Among authors: flament c. J Immunol. 2004 Feb 15;172(4):2126-36. doi: 10.4049/jimmunol.172.4.2126. J Immunol. 2004. PMID: 14764678
94 results